[Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)]. 2023

Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
VIVIT Institut Feldkirch, Feldkirch, Österreich.

Hypertension is one of the most important comorbidities of diabetes, contributing significantly to death and leading to macrovascular and microvascular complications. When assessing the medical priorities for patients with diabetes, treating hypertension should be a primary consideration. In the present review practical approaches to hypertension in diabetes, including individualized targets for preventing specific complications are discussed according to current evidence and guidelines. Blood pressure values of about 130/80 mm Hg are associated with the best outcome; most importantly, at least blood pressure values < 140/90 mm Hg should be achieved in most patients. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers should be preferred in patients with diabetes, especially in those who also have albuminuria or coronary artery disease. Most patients with diabetes require combination therapy to achieve blood pressure goals; agents with proven cardiovascular benefit should be used (including, besides angiotensin converting enzyme inhibitors and alternatively angiotensin receptor blockers, dihydropyridin-calcium antagonists and thiazide diuretics), preferable in single-pill combinations. Once the target is achieved, antihypertensive drugs should be continued. Newer antidiabetic medications such as SGLT-2-inhibitors or GLP1-receptor agonists have also antihypertensive effects.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D001317 Austria A country located in Central Europe, north of Italy and Slovenia. The capital is Vienna.
D057911 Angiotensin Receptor Antagonists Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR. Angiotensin II Receptor Antagonist,Angiotensin II Receptor Blocker,Angiotensin Receptor Antagonist,Angiotensin Receptor Blocker,Angiotensin II Receptor Antagonists,Angiotensin II Receptor Blockers,Angiotensin Receptor Blockers,Antagonist, Angiotensin Receptor,Antagonists, Angiotensin Receptor,Blocker, Angiotensin Receptor,Receptor Antagonist, Angiotensin,Receptor Antagonists, Angiotensin,Receptor Blocker, Angiotensin,Receptor Blockers, Angiotensin

Related Publications

Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
January 2023, Wiener klinische Wochenschrift,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
December 2012, Wiener klinische Wochenschrift,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
April 2016, Wiener klinische Wochenschrift,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
January 2023, Wiener klinische Wochenschrift,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
January 2023, Wiener klinische Wochenschrift,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
January 2023, Wiener klinische Wochenschrift,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
July 2023, Diabetology & metabolic syndrome,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
January 2023, Wiener klinische Wochenschrift,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
January 2007, Drugs & aging,
Christoph H Saely, and Gerit-Holger Schernthaner, and Johanna Brix, and Renate Klauser-Braun, and Emanuel Zitt, and Heinz Drexel, and Guntram Schernthaner
January 1990, Therapeutische Umschau. Revue therapeutique,
Copied contents to your clipboard!